Baloxavir Treatment to Reduce Influenza Virus Transmission

Timothy M Uyeki^{1

2}, Vivien G Dugan^{1

2}, Demetre C Daskalakis²

Affiliations

¹ Division of Influenza, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta.
² National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta.

Editorial

Timothy M Uyeki et al. N Engl J Med. 2025.

. 2025 Apr 24;392(16):1652-1654.

doi: 10.1056/NEJMe2503242.

Timothy M Uyeki^{1

2}, Vivien G Dugan^{1

2}, Demetre C Daskalakis²

¹ Division of Influenza, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta.
² National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta.

No abstract available

References

1. Uyeki TM, Bernstein HH, Bradley JS, et al. Clinical practice guidelines by the Infectious Diseases Society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenza. Clin Infect Dis 2019;68(6):e1–e47. - PMC - PubMed
1. Centers for Disease Control and Prevention. Influenza antiviral medications: summary for clinicians. December 3, 2023. (https://www.cdc.gov/flu/hcp/antivirals/summary-clinicians.html).
1. Hayden FG, Sugaya N, Hirotsu N, et al. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N Engl J Med 2018;379:913–23. - PubMed
1. Ison MG, Portsmouth S, Yoshida Y, et al. Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial. Lancet Infect Dis 2020;20:1204–14. - PubMed
1. Dobson J, Whitley RJ, Pocock S, Monto AS. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Lancet 2015;385:1729–37. - PubMed